

***Bacteroides fragilis*, Strain CL07T00C01**

Catalog No. HM-709

For research use only. Not for use in humans.

Contributor:

Laurie E. Comstock, Ph.D., Associate Microbiologist, Department of Medicine, Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Manufacturer:

BEI Resources

Product Description:

Bacteria Classification: *Bacteroidaceae*, *Bacteroides*

Species: *Bacteroides fragilis*

Strain: CL07T00C01

Original Source: *Bacteroides fragilis* (*B. fragilis*), strain CL07T00C01 was isolated from healthy adult feces in Massachusetts, USA.^{1,2}

Comments: *B. fragilis*, strain CL07T00C01 ([HMP ID 1055](#)) is a reference genome for [The Human Microbiome Project](#) (HMP). HMP is an initiative to identify and characterize human microbial flora. The complete genome of *B. fragilis*, strain CL07T00C01 was sequenced at the [Broad Institute](#) (GenBank: [AGXM00000000](#)).

Note: HMP material is taxonomically classified by the depositor. Quality control of these materials is only performed to demonstrate that the material distributed by BEI Resources is identical to the deposited material.

B. fragilis is a Gram-negative, anaerobic, non-motile bacterium that is both a normal colonic commensal, critical to host mucosal and systemic immunity, and an opportunistic pathogen.³ Although only a minor component of the human gut microflora (< 1%), *B. fragilis* isolates are the primary anaerobe in clinical specimens, bloodstream infections, and abdominal abscesses.⁴ Strains are classified as either nontoxigenic or enterotoxigenic *B. fragilis* (NTBF or ETBF, respectively), the latter secreting an extracellular metalloprotease toxin.^{4,5,6} All *B. fragilis* strains are presumed to be resistant to ampicillin and penicillin.⁷

Material Provided:

Each vial contains approximately 0.5 mL of bacterial culture in Modified Reinforced Clostridial broth supplemented with 10% glycerol.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

HM-709 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Media:

Modified Reinforced Clostridial broth or equivalent
Tryptic Soy agar with 5% defibrinated sheep blood or equivalent

Incubation:

Temperature: 37°C

Atmosphere: Anaerobic

Propagation:

1. Keep vial frozen until ready for use, then thaw.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate the tube, slant and/or plate at 37°C for 1 to 2 days.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH as part of the Human Microbiome Project: *Bacteroides fragilis*, Strain CL07T00C01, HM-709."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Comstock, L. E., Personal Communication.
2. [HMP ID 1055](#) (*Bacteroides fragilis*, strain CL07T00C01)
3. Troy, E. B. and D. L. Kasper. "Beneficial Effects of *Bacteroides fragilis* Polysaccharides on the Immune System." *Front. Biosci.* 15 (2010): 25-34. PubMed: 20036803.
4. Sears, C. L. "Enterotoxigenic *Bacteroides fragilis*: A Rogue Among Symbiotes." *Clin. Microbiol. Rev.* 22 (2009): 349-369. PubMed: 19366918.
5. Sears, C. L. "The Toxins of *Bacteroides fragilis*." *Toxicon* 39 (2011): 1737-1746. PubMed: 11595636.
6. Wexler, H. M. "*Bacteroides*: The Good, the Bad, and the Nitty-Gritty." *Clin. Microbiol. Rev.* 20 (2007): 593-621. PubMed: 17934076.
7. CLSI M100-S28 (2018)

ATCC® is a trademark of the American Type Culture Collection.

